Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation
Our findings reveal that DCAF5 exhibits context-dependent dual roles across cancers and demonstrates superior predictive value over traditional biomarkers like TMB in immunotherapy. This highlights its potential as a dual-functional biomarker for prognosis and immunotherapy personalization, particularly in SMARCB1-deficient malignancies.
Authors
- Rubing Li (ORCID: https://orcid.org/0000-0002-3269-6116)
- Tieding Chen
- Huaqing Yan (ORCID: https://orcid.org/0000-0001-9994-720X)
- Liqi Zhang (ORCID: https://orcid.org/0000-0002-6421-680X)
- Fan Xu (ORCID: https://orcid.org/0000-0003-2968-6483)
Institutions
- Ningbo University (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1007/s12672-025-02974-6
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Ningbo